A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
J. Choe, N. Prodanovic, J. Niebrzydowski, I. Staykov +11 more

